Erin Boyer
Human Resources Officer at UNIQURE N.V.
Profile
Erin Boyer is currently the Chief People & Culture Officer at uniQure NV since 2022.
Previously, she worked as the Head-Global Talent Strategy & Planning at Alnylam Pharmaceuticals, Inc., Chief People & Culture Officer at Epizyme, Inc., and Vice President-Human Resources at Obsidian Therapeutics, Inc. Ms. Boyer completed her undergraduate degree at Macalester College.
Erin Boyer active positions
| Companies | Position | Start |
|---|---|---|
| UNIQURE N.V. | Human Resources Officer | 01/04/2022 |
Former positions of Erin Boyer
| Companies | Position | End |
|---|---|---|
Obsidian Therapeutics, Inc.
 Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Human Resources Officer | - |
| ALNYLAM PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
| EPIZYME, INC. | Human Resources Officer | - |
Training of Erin Boyer
| Macalester College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ALNYLAM PHARMACEUTICALS, INC. | Health Technology |
| UNIQURE N.V. | Health Technology |
| Private companies | 2 |
|---|---|
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Erin Boyer
